WORLD TRADE  
ORGANIZATION  WT/DS48/21 
8 January 2009 
 (09-0026) 
 Original:   English 
  
 
EUROPEAN COMMUNITIES – MEASURES CONCERNING 
MEAT AND MEAT PRODUCTS (HORMONES) 
 
Recourse to Article 21.5 of the DSU by the European Communities
 
 
Request for Consultations 
 
  The following communication, dated 22 Decembe r 2008, from the delegation of the European 
Communities to the delegation of Canada and to th e Chairman of the Dispute Settlement Body, is 
circulated in accordance with Article 21.5 of the DSU. 
 
_______________ 
 
  The European Communities hereby requests c onsultations with Cana da under Articles 21.5 
and 4 of the Understanding on Rules and Procedures Governing the Settlement of Disputes  ("DSU").   
  On 16 September 1996 Canada requested the establishment of a panel, referring to the 
following measures:  
The European Communities measures prohibi ting the importation of livestock and 
meat from livestock that have been treated  with certain substances having a hormonal 
action ("EC measures") include the following:  Council Directive 88/146/EEC;  the directives referenced in that directive (72/462/EEC, 81/602/EEC, 81/851/EEC, 81/852/EEC, and 85/358/EEC);  the decisions re ferred to in Article 6(2) of directive 
88/146/EEC;  the control programme referred to in Article 6(7) of directive 88/146 
EEC;  the derogations referred to in Ar ticle 7 of directive 88/146/EEC;  and any 
amendments or modifications, includin g Council Directives 96/22/EC and 96/23/EC.
1 
 The original panel report states that the disput e concerned in particular Directive 81/602/EEC, 
Directive 88/146/EEC and Directive 88/299/EEC,2 and refers to other measures relevant to the 
dispute, including Directive 96/22.3 The original panel report also records that on 29 April 1996 the 
European Communities adopted Directive 96/22, replacing Directive 81/602/EEC, Directive 
88/146/EEC and Directive 88/299/EEC;4 and that EC Member States were required to comply with 
Directive 96/22 by 1 July 1997 at the latest.5 The original panel report explains that, inter alia , these 
measures prohibited or restricted the administering to farm animals of six hormones, or the placing on 
                                                      
1 WT/DS48/5, 16 September 1996. 
2 Panel Report, EC – Hormones (Canada) , WT/DS48/R/CAN, para. 2.1. 
3 Panel Report, EC – Hormones (Canada) , footnote 2. 
4 Council Directive 96/22/EC of 29 April 1996 concerning the prohibition on the use in stockfarming 
of certain substances having a hormonal or thyrostatic action and of beta-agonists, and repealing Directives 
81/602/EEC, 88/146/EEC and 88/299/EEC ( Official Journal of the European Communities  L 125 of 23 May 
1996, p. 3). 
5 Panel Report, EC – Hormones (Canada) , para. 2.5. WT/DS48/21 
Page 2  
 
  the market of animals or meat from animals to  which such hormones have been administered.
6 The six 
hormones involved in the dispute were: oestradiol 17 β; testosterone; progesterone; trenbolone acetate; 
zeranol; and melengestrol acetate (MGA).7 Canada claimed that, as a result of these measures, there 
was discrimination against Canadian beef imports and a disguised restriction on international trade.8 
 
 On 13 February 1998, the Dispute Settlement  Body ("DSB") adopted the Appellate Body 
report in European Communities – Measures Concerning Meat and Meat Products (Hormones) ("EC 
– Hormones" ) and the panel report as modified by the Appellate Body report.9 The Appellate Body 
upheld the panel's findings that the measures we re inconsistent with  Article 5.1 of the SPS Agreement , 
because they were not based on a risk assessment within the meaning of Articles 5.1 and 5.2 of the 
SPS Agreement .10  The Appellate Body recommended that the DSB request the European 
Communities to bring the SPS measures found in the A ppellate Body report and in the panel report, as 
modified by the Appellate Body repor t, to be inconsistent with the SPS Agreement  into conformity 
with the obligations of the European Communities under that Agreement.   
 In light of the DSB recommendations and rulings in EC – Hormones , and in order to comply 
with them, the European Communities initiated a nd funded a number of specific studies and research 
projects, requested third countries (including Canada) for any scientific data and information in their 
possession, reviewed the findings of independent e xpert bodies, taking into account information from 
relevant international organisati ons, and performed an extensive review of the available scientific 
evidence and of available pertinent informa tion concerning the six substances at issue.
11  F o r  
oestradiol 17 β, the European Communities disposed of suffi cient scientific evidence to perform a risk 
assessment within the meaning of Article 5.1 of the SPS Agreement.  For the other five substances, 
having regard to the European Communities appropr iate level of protection, relevant scientific 
evidence was insufficient for perform ing a risk assessment within the meaning of Article 5.1 of the 
SPS Agreement , and risk assessments within the meaning of Article 5.7 of the SPS Agreement  were 
performed on the basis of available pertinent information.  
  Based on these risk assessments and on the basis of all other available pertinent information, 
the European Communities a dopted Directive 2003/74/EC,
12 which entered into force on 14 October 
2003.13 Pursuant to Directive 2003/74/EC, there is a permanent prohibition for the placing on the 
                                                      
6 Panel Report, EC – Hormones (Canada) , paras 2.1 to 2.5. 
7 Panel Report, EC – Hormones (Canada) , paras 2.8 to 2.9; Appellate Body Report, EC – Hormones , 
paras 2 to 5. 
8 Panel Report, EC – Hormones (Canada) , para. 3.1, final sentence. 
9 Action by the Dispute Settlement Body (WT/DS48/11, 19 February 1998); Appellate Body report 
(WT/DS48/AB/R, 16 January 1998); Panel Report (WT/DS48/R/CAN, 18 August 1997). 
10 Appellate Body Report, EC – Hormones , paras 253(l) and 208. 
11 Opinion of the Scientific Committee on Veterinary  Measures Relating to Public Health (SCVPH): 
Assessment of potential risks to human health from hormone residues in bovine meat and meat products 
(30 April 1999); Opinion on review of previous SCVPH opinions of 30 April 1999 and 3 May 2000 on the 
potential risks to human health from hormone residues in bovine meat and meat products (adopted on 10 April 2002) and Review of specific documents relating to the SCVPH opinion of 30 April 99 on the potential risks to 
human health from hormone residues in bovine meat and meat products (adopted on 3 May 2000). These 
opinions have been made available to the public and are still accessible on: 
http://ec.europa.eu/food/food/chemicalsafety/contaminants/hormones/sci_opinion_en.htm. 
12 Directive 2003/74/EC of the European Parliament and of the Council of 22 September 2003 
amending Council Directive 96/22/EC concerning the prohibition on the use in stockfarming of certain substances having a hormonal or thyrostatic action and of beta-agonists ( Official Journal of the European Union  
L 262 of 14 October 2003, p. 17).  Recitals 1-13 of Directive 2003/74/EC summarise the reasons for its 
adoption. 
13 Directive 96/22/EC was most recently amende d by Directive 2008/97/ EC of the European 
Parliament and the Council of 19 November 2008 amending Council Directive 96/22/EC concerning the  WT/DS48/21 
 Page 3 
 
 
  market of meat and meat products fro m animals treated with oestradiol 17 β for growth-promotion 
purposes, and a provisional prohibition for the placing on the market of meat and meat products from animals treated with testosterone, progesterone, trenbolone acetate, zeranol and melengestrol acetate (MGA) for growth-promotion purposes, pending  the obtaining of additional information.
14  
 
 The European Communities continues to observe scientific developments in this area and 
gathers additional information on these five substa nces. In June 2007, the European Food Safety 
Authority completed another review of the availabl e pertinent information and concluded that the new 
data did not call for a revision of the previous assessments of the Scientific Committee on Veterinary 
Measures relating to Public Health that were performed in 1999, 2000 and 2002.15  
 
 The European Communities considers that by  gathering and analysing all the available 
pertinent scientific and other evidence, by perfo rming risk assessments,  by adopting Directive 
2003/74/EC, by properly notifying it to the WTO, and by continuing to seek to obtain additional information on testosterone, progesterone, trenbo lone acetate, zeranol and melengestrol acetate 
(MGA), it has brought the measures found to be inc onsistent into compliance with the relevant 
provisions of the SPS Agreement , in line with the recommendations and rulings of the DSB. This 
remains the case as of the date of this consultation request.   In light of the above, the European Communiti es considers that the measures taken to comply 
are: 
 
– in compliance with Article 5.1 of the SPS Agreement , as far as oestradiol 17 β is concerned, 
since it is "based on an assessment, as appropriate  to the circumstances, of the risk to human 
[…] life or health, taking into account risk assessment techniques developed by the relevant 
international organisations"; and 
 
– in compliance with Article 5.7 of the SPS Agreement , as far as testosterone, progesterone, 
trenbolone acetate, zeranol and melengestrol acet ate (MGA) are concerned, since for each of 
these substances the "relevant scien tific evidence is insufficient" , the measure is maintained 
"provisionally" and "on the basis of available pertinent information, including that from the 
relevant international organizations as we ll as from sanitary or phytosanitary measures 
applied by other Members", and the European  Communities sought "to obtain the additional 
information necessary for a more objective assess ment of risk and review the sanitary or 
phytosanitary measure accordingly w ithin a reasonable period of time". 
  The European Communities therefore considers that the conditions in the first sentence of 
Article 22.8 of the DSU have been met and, as a co nsequence, Canada must terminate the suspension 
of concessions without delay.   
                                                                                                                                                                    
 
prohibition on the use in stockfarming of certain substances having a hormonal or thyrostatic action and of beta-
agonists ( Official Journal of the European Union  L 318 of 28 November 2008, p. 9). 
14 The European Communities notified the DSB of the adoption of Directive 2003/74/EC with a 
Communication on 27 October 2003, circulated und er reference WT/DS26/22, where the European 
Communities stated that it considered that it had fully implemented the recommendations and rulings of the 
DSB and, as a consequence, the susp ension of concessions to the EC by the United States and Canada was no 
longer justified. 
15 Opinion of the Scientific Panel on contaminants in the food chain (CONTAM) related to hormone 
residues in bovine meat and meat products, question number: EFSA-Q-2005-048, adopted on 12 June 2007, published in The EFSA Journal (2007) 510, pages 1 – 62, available on: 
http://www.efsa.europa.e u/EFSA/efsa_locale-1178620753812_1178622336805.htm. WT/DS48/21 
Page 4  
 
   The European Communities understands that the Canada disagrees with these positions, as 
demonstrated by the fact that Canada maintain s the suspension of concessions to the European 
Communities by continuing to impose import duties in excess of bound rates on imports from the European Communities.   
 With these consultations, the European Co mmunities intends to enable the European 
Communities and Canada to resolve their disagreem ent on the substantive compliance with the DSB 
rulings and recommendations achieved by the measu res taken to comply, and to have Canada 
terminate the suspension of concessions immediately.    
 The European Communities looks forward to r eceiving in due course Canada's reply to this 
request and to setting a mutually convenient  date and modality for these consultations.  
 
__________